Health

/

ArcaMax

Cannabis-Based Drug Approved For Cancer Treatment In Peru

By Benzinga Staff Writer, The Fresh Toast on

Published in Cannabis Daily

Sativyl contains a 27 mg/ml concentration of THC (tetrahydrocannabinol) and 25 mg/ml of CBD. It’s sold by the flask and contains 10 ml and 250 mg of concentration. An Alternative To Classic Antiemetics

Sativyl also works to control nausea caused by chemotherapy treatment. The antiemetic performance of the medication improves the patient's appetite and, consequently, their physical condition to face the therapy.

Sativyl contains a 27 mg/ml concentration of THC (tetrahydrocannabinol) and 25 mg/ml of CBD. It’s sold by the flask and contains 10 ml and 250 mg of concentration.

RELATED: Breast Cancer Patients Are Using Cannabis, But Many Are Lacking This Important Step

The medicine itself is produced in Canada by the pharmaceutical company Verdemed, in partnership with the Toronto Institute of Pharmaceutical Technology.

[caption id="attachment_171750" align="alignnone" width="696"] Photo by Rocky89/Getty Images[/caption]

“In January of next year, we’ll have Sativyl on the Peruvian market,” says José Bacellar, the company’s CEO. “We believe it will cost a third of Mevatyl [the Brazilian version of Sativex], coming up to a mere R$500 [$89.60].”

 

RELATED: Cancer Patients Say Cannabis Is Just As Effective Or Better Than Cancer Treatments

The Peruvian health license was approved less than one month after Verdemed received the Brazilian Sanitary Agency (ANVISA) approval to distribute full spectrum 50 mg/ml CBD, a medicine developed in partnership with the American-Colombian company Clever Leaves. Documentation for Sativyl has already been submitted to ANVISA (the Brazilian equivalent of the FDA) for analysis.

This article originally appeared on Benzinga and has been reposted with permission.

The Fresh Toast is a daily lifestyle platform with a side of cannabis. For more information, visit www.thefreshtoast.com.

The Fresh Toast